Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
This randomized phase II/III trial studies how well giving combination chemotherapy with or
without rituximab works in treating younger patients with stage III or stage IV non-Hodgkin
lymphoma or B-cell acute leukemia. Drugs used in chemotherapy work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibody, such as rituximab, can block cancer cells growth in different ways.
Some block the ability of cancer cells to grow and spread. Others find cancer cells and help
kill them or carry cancer-killing substances to them. It is not yet known whether giving
combination chemotherapy together with rituximab is more effective in treating patients with
non-Hodgkin lymphoma or B-cell acute leukemia.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.